Cite
MLA Citation
P.A. Hamlin et al.. “THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES.” Hematological oncology, vol. 35, n.d., p. 74. http://access.bl.uk/ark:/81055/vdc_100047473605.0x00002c